Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial (Q39349036)

11 September 2017

Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial (English)

1 reference

Sander Veldhuyzen van Zanten

11 September 2017

0 references

0 references

1 reference

1

object named as

Sander Veldhuyzen van Zanten

1 reference

11 September 2017

David Armstrong

2

1 reference

11 September 2017

Naoki Chiba

3

1 reference

11 September 2017

Nigel Flook

4

1 reference

11 September 2017

Robert J White

5

1 reference

11 September 2017

Bijan Chakraborty

6

1 reference

11 September 2017

Ally Gasco

7

1 reference

11 September 2017

language of work or name

English

0 references

publication date

30 June 2006

1 reference

The American Journal of Gastroenterology

11 September 2017

1 reference

11 September 2017

101

1 reference

11 September 2017

9

1 reference

11 September 2017

2096-2106

1 reference

Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies).

11 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Measurement of health status. Ascertaining the minimal clinically important difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Does endoscopy have a positive impact on quality of life in dyspepsia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Functional dyspepsia: bye-bye to PPIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

Comprehension and awareness of symptoms in women with dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00751.X

10.1111/J.1572-0241.2006.00751.X

21 January 2018

Identifiers

DOI

1 reference

release_ll4cjnsfl5fprezfaqqaxu247e

11 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ll4cjnsfl5fprezfaqqaxu247e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference